Home Featured Page 201

Featured

Latest

The Psychedelic News Feed: December 8 – 14, 2025

The Psychedelic Practitioner Issue 2: Preparation

Evidence and Experience: Samuel Wilkinson on the State of (Es)ketamine Therapy and What Comes Next

The Psychedelic News Feed: December 1 – 7, 2025

The Psychedelic News Feed: November 24 – 30, 2025

Mydecine Secures Financing and Provides Company Update on Clinical Trials, Drug...

Numinus Wellness Inc. Reports Q4 and Year End 2021 Results

Algernon Pharmaceuticals Completes Manufacturing of Psychedelic Drug DMT Appoints UK Stroke...

PsyBio Therapeutics Successfully Completes First Pre-IND Meeting with the United States...

Mydecine Files Full Patent Application Covering Multiple Families of Psilocin Analogs

PTSF88 – Dr. Ben Sessa of Awakn Life Sciences + Josh...

atai Life Sciences launches TryptageniX to further expand atai’s robust intellectual...

Editor’s Choice Award 2021-Best Study on Psychedelics and Pharmacology

MindMed Engages in Productive Pre-Submission Meeting with FDA for Development of...

Delix Therapeutics Partners with the National Institute on Drug Abuse (NIDA)...

1...200201202...304 Page 201 of 304

The Psychedelic News Feed: December 8 – 14, 2025

The Psychedelic Practitioner Issue 2: Preparation

Evidence and Experience: Samuel Wilkinson on the State of (Es)ketamine Therapy...

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

The Psychedelic News Feed: December 8 – 14, 2025

The Psychedelic Practitioner Issue 2: Preparation

Evidence and Experience: Samuel Wilkinson on the State of (Es)ketamine Therapy and What Comes Next

The Psychedelic News Feed: December 1 – 7, 2025

The Psychedelic News Feed: November 24 – 30, 2025

Mydecine Secures Financing and Provides Company Update on Clinical Trials, Drug...

Numinus Wellness Inc. Reports Q4 and Year End 2021 Results

Algernon Pharmaceuticals Completes Manufacturing of Psychedelic Drug DMT Appoints UK Stroke...

PsyBio Therapeutics Successfully Completes First Pre-IND Meeting with the United States...

Mydecine Files Full Patent Application Covering Multiple Families of Psilocin Analogs

PTSF88 – Dr. Ben Sessa of Awakn Life Sciences + Josh...

atai Life Sciences launches TryptageniX to further expand atai’s robust intellectual...

Editor’s Choice Award 2021-Best Study on Psychedelics and Pharmacology

MindMed Engages in Productive Pre-Submission Meeting with FDA for Development of...

Delix Therapeutics Partners with the National Institute on Drug Abuse (NIDA)...

EDITOR PICKS

The Psychedelic News Feed: December 8 – 14, 2025

The Psychedelic Practitioner Issue 2: Preparation

Evidence and Experience: Samuel Wilkinson on the State of (Es)ketamine Therapy...

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY